Rapid Readout: Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2+ Metastatic Breast Cancer: DESTINY-Breast03

Video

Sara A. Hurvitz, MD, discusses findings from the DESTINY-BREAST03 trial that were presented at the 2021 San Antonio Breast Cancer Symposium that compare trastuzumab deruxtecan (T-DXd) with trastuzumab emtansine (T-DM1) for patients with HER2+ metastatic breast cancer.

OncLive® Rapid Readout from San Antonio Breast Cancer Symposium: Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2+ Metastatic Breast Cancer: Subgroup Analyses From the Randomized Phase 3 Study DESTINY-Breast03

Segment Description: Sara A. Hurvitz, MD, discusses findings from the DESTINY-BREAST03 trial that were presented at the 2021 San Antonio Breast Cancer Symposium that compare trastuzumab deruxtecan (T-DXd) with trastuzumab emtansine (T-DM1) for patients with HER2+ metastatic breast cancer. (Abstract GS3-01)

Segment Body Content:

T-DXd is a HER2-targeting antibody-drug conjugate approved for the treatment of pts with advanced HER2+ mBC based on the DESTINY-Breast01 study (NCT03248492). DESTINY-Breast03 (NCT03529110) is a randomized, multicenter, open-label, phase 3 study assessing the efficacy and safety of T-DXd vs T-DM1 in pts with HER2+ mBC previously treated with trastuzumab and taxanes. In the primary analysis, T-DXd demonstrated a clinically meaningful and statistically significant improvement in PFS vs T-DM1 (Corteset al, ESMO 2021). In this exploratory analysis, we provide additional efficacy and safety data in subgroups, including in pts with brain metastases (BMs).

Methods

  • Pts were randomly assigned 1:1 to receive 5.4 mg/kg T-DXd or 3.6 mg/kg T-DM1 Q3W. Pts with clinically stable BMs were eligible. Lesions were measured per modified Response Evaluation Criteria in Solid Tumors version 1.1.
  • The primary endpoint was progression-free survival (PFS) determined by blinded independent central review (BICR). PFS and overall response rate (ORR) were analyzed for subgroups. Sites of progression and post-end-of-study therapies were also investigated.

Results

  • At data cutoff (May 21, 2021), 524 pts were randomly assigned to T-DXd (n=261) orT-DM1 (n=263). T-DXd demonstrated superior PFS by BICR vs T-DM1 (HR, 0.28 [95%CI, 0.22-0.37]; P=7.8 x 10-22); median (m) PFS by BICR was not reached (95% CI, 18.5-NE) for T-DXd compared with 6.8 mo (95% CI, 5.6-8.2) forT-DM1. For pts with stable BMs at baseline (n=82), mPFS was 15.0 mo (95% CI,12.5-22.2) for T-DXd vs 3.0 mo (95% CI, 2.8-5.8) for T-DM1 (HR, 0.25 [95% CI,0.31-0.45)].
  • Overall, confirmed ORR for T-DXd was 79.7% vs 34.2% for T-DM1. For patients with stable BMs at baseline, ORR was 67.4% for T-DXd vs 20.5% forT-DM1.
  • Consistent PFS and ORR benefit was also observed across other subgroups. At data cutoff, 84 (32.2%) pts treated with T-DXd had progressive disease (PD) vs 155 (58.9%) with T-DM1. In pts with stable BMs in the T-DXd arm, 48.8% of pts (21/43) had PD. In pts with stable BMs in the T-DM1 arm, 69.2%of pts (27/39) had PD.
  • Data on sites of progression will be presented. Further analyses are underway and will be presented.
  • Overall, the safety profile of T-DXd was manageable and comparable with its known safety profile. Adjudicated drug-related interstitial lung disease/pneumonitis was reported in 27 (10.5%) pts treated with T-DXd and 5 (1.9%) pts treated with T-DM1 overall, with no grade 4 or 5 events. Additional new safety data will be presented.

Conclusion

DESTINY-Breast03, the first-reported randomized phase 3 trial comparing T-DXd to standard of care, met the primary endpoint with T-DXd demonstrating superior PFS vs T-DM1 and T-DXd had a manageable safety profile. In this exploratory analysis, consistent PFS and ORR benefit with T-DXd vs T-DM1 was observed across subgroups in pts with HER2+ mBC previously treated with trastuzumab and taxane, including in pts with BMs.

Related Videos
Joshua K. Sabari, MD, an expert on lung cancer, presenting slides
Yelena Y. Janjigian, MD, an expert on gastrointestinal cancer
Guru P. Sonpavde, MD, an expert on urothelial carcinoma
Related Content